Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07061847 · ClinicalTrials.gov registry record · Phase 2
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
A Phase 2 study of Migraine, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07061847 is a Phase 2 study of Migraine that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 40 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07061847, a Phase 2 study of Migraine, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, frequency, and duration.
Conditions Studied
Interventions
- DRUG Lidocaine (drug)
- PROCEDURE Lidocaine Procedure
Study Locations (1)
New York
- Neuroscience Institute at Great Neck - Great Neck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07061847
The ClinicalTrials.gov registry entry for NCT07061847 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (89% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine (drug) is the first listed.
NCT07061847 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07061847 about?
NCT07061847 is a clinical study titled "Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines". The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, ...
What is the current status of trial NCT07061847?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-03-10. Estimated completion is 2027-06-30.
What conditions does trial NCT07061847 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT07061847?
The interventions under investigation include: Lidocaine (drug) (DRUG), Lidocaine Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT07061847?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07061847 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
-
CHOCOlate MeLatonin for AdolescenT MigrainE
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.